SLDB
Solid Biosciences Inc.
NASDAQ · Healthcare · Biotechnology · US
$5.92
+7.05%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -35.1%
- EBIT
- -35.3%
- EPS
- +26.5%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- -34.5%
- EPS
- +10.6%
Three-year CAGR
- Revenue
- —
- EBITDA
- -41.7%
- EBIT
- -38.1%
- Net income
- -39.8%
- EPS
- +35.0%
- Free cash flow
- -56.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026